1. Home
  2. SOWG vs PMVP Comparison

SOWG vs PMVP Comparison

Compare SOWG & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

N/A

Current Price

$2.31

Market Cap

69.9M

ML Signal

N/A

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

N/A

Current Price

$1.30

Market Cap

72.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOWG
PMVP
Founded
2010
2013
Country
United States
United States
Employees
N/A
54
Industry
Packaged Foods
Medicinal Chemicals and Botanical Products
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.9M
72.2M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
SOWG
PMVP
Price
$2.31
$1.30
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $4.20
AVG Volume (30 Days)
5.3K
★ 554.8K
Earning Date
11-13-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.10
$1.02
52 Week High
$15.90
$1.91

Technical Indicators

Market Signals
Indicator
SOWG
PMVP
Relative Strength Index (RSI) 46.28 46.41
Support Level $2.10 $1.24
Resistance Level $2.62 $1.31
Average True Range (ATR) 0.18 0.11
MACD 0.05 -0.00
Stochastic Oscillator 82.29 51.90

Price Performance

Historical Comparison
SOWG
PMVP

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: